Stockreport

Immunovant Announces $450 Million Private Placement

Immunovant, Inc.  (IMVT) 
PDF NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with aut [Read more]